gram-negative infections were documented, including the 9 cases of *A. xylosoxidans* reported herein (1.6% of all patients). This bacteria can be found in aqueous environments, such as disinfectants and fluids. Thus, we might suspect in a common source, but there was no epidemiological relationship between cases. Moreover, three episodes were diagnosed as outpatients.

In our series, the majority of patients had severe neutropenia, and it is possible that mucositis and breakdown of the intestinal barrier allowed invasion of bloodstream by *A. xylosoxidans*. Clinical presentations were highly persistent fever and chills, but neither death nor sepsis syndrome occurred despite poor response to antibiotic therapy in most cases. This is in contrast with other non-fermenting gram-negative infections, which are often associated with high morbidity and mortality.8

The antibiotic susceptibility profile of isolates was similar to previous reports,4,5 with special emphasis on the almost universal in vitro resistance to aminoglycosides and aztreonam. As with other non-fermenting gram-negative bacilli, most isolates were susceptible to broad-spectrum β-lactams, co-trimoxazole and fluoroquinolones. The most important conclusion, from our experience, is that these infections are usually catheter-related, and despite their apparently low morbidity, removal of the catheter is generally required for definitive eradication of the microorganism. Appropriate in vitro antibiotic therapy may be ineffective or lead only temporary control of the infection.

**Key words**
Bacteremia, hematologic malignancies

**Correspondence**
José Angel Hernández, Servei d’Hematologia-Hematopatia, Hospital Universitari Germans Trias i Pujol, Ctra. Canyet s/n, 08916 Badalona (Barcelona), Spain. Fax: international +34-3-3954206.

**Table 2. Patient characteristics. II.**

<table>
<thead>
<tr>
<th>Pts</th>
<th>Catheter infection</th>
<th>Primary treatment</th>
<th>Response</th>
<th>Secondary treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>yes</td>
<td>imipenem+amikacin</td>
<td>refractory</td>
<td>CR</td>
<td>cure</td>
</tr>
<tr>
<td>2</td>
<td>yes</td>
<td>imipenem+amikacin</td>
<td>refractory</td>
<td>CR</td>
<td>cure</td>
</tr>
<tr>
<td>3</td>
<td>yes</td>
<td>imipenem+amikacin</td>
<td>cure</td>
<td>none</td>
<td>cure</td>
</tr>
<tr>
<td>4</td>
<td>yes</td>
<td>ceftazidime+amikacin</td>
<td>refractory</td>
<td>CR</td>
<td>cure</td>
</tr>
<tr>
<td>5</td>
<td>yes</td>
<td>ceftazidime+amikacin</td>
<td>relapse</td>
<td>CR</td>
<td>cure</td>
</tr>
<tr>
<td>6</td>
<td>yes</td>
<td>ceftazidime+amikacin</td>
<td>cure</td>
<td>none</td>
<td>cure</td>
</tr>
<tr>
<td>7</td>
<td>yes</td>
<td>CR</td>
<td>cure</td>
<td>none</td>
<td>cure</td>
</tr>
<tr>
<td>8</td>
<td>no</td>
<td>clinafloxacn+CR</td>
<td>cure</td>
<td>none</td>
<td>cure</td>
</tr>
<tr>
<td>9</td>
<td>yes</td>
<td>imipenem+amikacin</td>
<td>refractory</td>
<td>CR</td>
<td>cure</td>
</tr>
</tbody>
</table>

CR: catheter removal.

**References**


**Unexpected late graft failure 9 months after HLA-identical bone marrow transplant (BMT) for chronic myeloid leukemia (CML): treatment with a second BMT**

**JUAN JOSÉ GIL-FERNÁNDEZ, REYES ARRANZ, RAFAEL CÁMARA, ADRIAN ALEGRE, ANGELA FIGUERA, JOSÉ MARÍA FERNÁNDEZ-RAÍADA**

Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain

We describe a patient with CML in 1st chronic phase (CP) who experienced a graft failure 9 months after an HLA genotypically identical sibling BMT. Drug toxicity, viral infections, chronic graft-versus-host-disease (GVHD) or leukemic relapse were excluded. Chimerism study showed 85% of donor marrow cells. She underwent a second BMT, reengrafted but died of grade IV acute GVHD.

Late graft failure (LGF) after allogeneic BMT is defined as pancytopenia with marrow hypoplasia after complete engraftment.1 It is observed after haplo-identical or T-cell-depleted BMT and in heavily transfused aplastic anaemia patients receiving identical grafts.2,3 The reported incidence of this event is about 0.4%.3 Cyclosporine withdrawal, interferon-α treat-
LGF has been rarely described after unmanipulated grafts for CML.\textsuperscript{5,6} In previously reported cases of LGF occurring more than 6 months after BMT, a cause could be found (T-cell depletion, HHV-6 infection, chronic GVHD or leukemic relapse).\textsuperscript{5,8} The mechanism of LGF is unknown.\textsuperscript{11} Residual host lymphocytes with \textit{in vitro} inhibitory effect against donor hematopoietic cells have been sometimes detected.\textsuperscript{6} Second transplants have a high transplant-related mortality in this condition.\textsuperscript{2,10} and immunosuppression treatment alone or combined with stem cells reinfusion or hematopoietic growth factors.\textsuperscript{1,4,5,8,9} frequently induce autologous hematopoietic recovery.\textsuperscript{1,8}

In our patient, a second BMT was decided because of the long interval between first BMT and graft failure and good patient’s performance status. Engraftment was successful but lethal GVHD developed. The optimal approach to manage this complication is unclear and reports are scarce and heterogeneous.

**Key words**

HLA-identical BMT, chronic myeloid leukemia, graft failure

**Correspondence**

Juan José Gil-Fernández, MD, Hematology Department, Hospital Universitario de la Princesa, Diego de León 62, 28006 Madrid, Spain. Fax: international +34-1-520-23-26.

**References**


Primary orbital lymphoma: contralateral relapse after six years in complete remission

Teresa Olave, Gemma Azaceta, Luis Palomera
Hematology Department, Hospital Clinico Universitario, Zaragoza, Spain

We report a patient diagnosed of an intermediate-grade primary orbital lymphoma with relapse in the other orbit after six years in complete remission (CR).

Primary orbital lymphoma (POL) comprises about 5-10% of all orbital neoplasms. Most common symptoms are exophthalmus and diplopia. POL is usually diagnosed at early stage, and shows low to intermediate-grade histology. Radiotherapy (36-40 Gy) is a successful treatment in most patients, so this entity has a favorable prognosis, with long free disease survival. However, we report a patient diagnosed of an intermediate-grade POL with relapse in the other orbit after six years in complete remission (CR).

A 35-year-old man with persistent right exophthalmus and visual impairment, was diagnosed of intermediate-grade POL after undergoing biopsy of a retrocular mass. The extension of disease was evaluated by computerized tomography (CT) scan and magnetic resonance (MR). No other lymphomatous locations were found. CR was achieved after systemic chemotherapy and local radiotherapy (40 Gy). After 6 years, left exophthalmus was noticed. A left orbital mass was detected by MR. The histological examination revealed the same intermediate-grade pattern. The imaging diagnosis showed no spread disease. Chemotherapy and radiotherapy were administered. Nowadays the patient remains in CR.

We have not found any other reference in the literature about contralateral relapse of POL. However, although POL usually shows indolent course and good prognosis, we suggest a long term follow up, in order to diagnose late relapse.

Key words
Orbital neoplasms, relapse, extranodal lymphoma

Correspondence
Teresa Olave Rubio, MD, Hematology Department, Hospital Clinico Universitario de Zaragoza, San Juan Bosco 15, 50009 Zaragoza, Spain. Phone: international +34-76-556400 • Fax: international +34-76-565955.

References

Recent advances in myelodysplastic syndromes (MDS)

Edoardo Ascari
Medicina Interna ed Oncologia Medica, IRCCS Policlinico S. Matteo, Pavia, Italy

This year Haematologica reports a series of review articles on Recent Advances in Myelodysplastic Syndromes: the first one appeared in the January issue, the second one is found in this issue. Future articles will analyze prognostic factors, secondary MDS and therapy of these disorders. The basis for this series has been the Fourth International Symposium on Myelodysplastic Syndromes held in Barcelona, Spain, on April 24-27, 1997. The Meeting organizers – Guillermo F. Sanz, Miguel A. Sanz and Teresa Vallespi – have done a remarkable job as Guest Editors. In 1997 Haematologica published several articles on MDS and is now proud of publishing this series, which will hopefully appear also as a separate print and electronic volume.

Key words
Myelodysplastic syndromes

Correspondence
Edoardo Ascari, Medicina Interna ed Oncologia Medica, IRCCS Policlinico S. Matteo, 27100 Pavia, Italy. E-mail: ascari@smatteo.pr.it

References
3. Elghetany MT, Hudnall SD, Gardner FH. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Haematologica